IL1B and breast cancer: The treatment with only AZA or both concentrations of BC (33 μM and 75 μM) did not interfere with proliferation with respect to the control (NS), while in co-treatment with IL-1β, we observed that both concentrations of BC were able to interfere with IL-1β-induced proliferation (p < 0.0005), contrarily to AZA/IL-1β co-treatment that showed differences with respect to the IL-1β treatment (Figure 1C).